Field notes on what we're seeing in ASC screening, agency workflow, and what's changing in Philippine advertising.
The fee is the smallest cost. The real budget items are revision cycles, missed launch windows, and substantiation research. Here's the full picture.
When cosmetic before/after frames are okay, when they cross into drug-claim territory, and the qualifiers the ASC expects.
When influencer content counts as advertising, who carries the liability, and what disclosure is actually required under the 2024 ASC Code.
Direct comparison is allowed in five categories. Everywhere else, indirect comparison with strict qualifiers is the line. Here's the working rule.
Three regulators, three different jobs. ASC reviews content. MTRCB classifies media. FDA registers the product. Where they overlap matters.
Digital used to be the workaround. The 2024 Code revision changed that. Here's what's now in scope and how to adjust the workflow.
Three structural reasons rejections are up — and the workflow change that absorbs them without slowing your launch calendar.